NERA is delighted to sponsor the Summit on Biosimilars in New York City on 24–25 June.

Managing Director Dr. Christine Meyer will participate in the session titled “The Growing Antitrust Scrutiny of Biosimilars and Biologics Manufacturers and Linked Settlement Considerations” on 25 June. Dr. Meyer and other panelists will discuss:

• The Pfizer v. Johnson & Johnson case;
• The FTC’s review of Paragraph IV settlement agreements;
• The FDA’s scrutinization of potential abuses of the citizen petition process; and
• How to understand the FTC’s coordination with the FDA.

Director Dr. David Blackburn will participate in the session titled “The Economics of Biosimilar Drugs: New Considerations for Market Access, Sustainable Pricing and Reimbursement Policies” on 25 June.  Dr. Blackburn and other panelists will discuss how effective biosimilar drugs have been in lowering drug prices and detail changes for how they are being reimbursed.